कंपनी लोड हो रही है
Just reported
Q3 2026 results
From Caris Life Sciences's results release of 4 नवंबर 2026; its quarterly report has since been filed.
Revenue
Actual
$275.4M
+27% y/y
+4.4% q/qGuided
—
No guide given
EPS, GAAP
Actual
$0.05
-38% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
$19.3M
-41% y/y
-28% q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$1.04B – $1.05B+29% y/y Raised +1.0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 अक्टू॰ 2026CBGraded C, now B
MCKMckesson Corporation4 नव॰ 2026BAGraded B, now A
CVSCVS Health Corp4 नव॰ 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 नव॰ 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 अक्टू॰ 2026CAGraded C, now A
कमाई कैसे होती है
- Molecular profiling services97%
- Pharma research and development services4%
आमदनी के हिस्से six months ended June 30, 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
मुकाबला किनसे है
क्या बेचती है6
MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.
3 और दिखाएँ
Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.
कौन खरीदता है4
- Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
- Government and commercial health insurers pay for some patient tests when they cover the test and its use.
- Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
- Academic cancer centers and researchers use Caris data and collaborate on cancer research.
किस पर टिका है, और क्या इसे तोड़ सकता है
कारोबार किन चीज़ों पर टिका है
- 1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
- 2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
- 3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
- 4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.
क्या ग़लत हो सकता है
- 1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
- 2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
- 3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.
Caris Life Sciences, Inc. के बारे में
Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.
- मुख्यालय
- Irving, Texas
- स्थापना
- 2008
- सूचीबद्ध
- Nasdaq
- वित्त वर्ष का अंत
- December 31
Caris Life Sciences, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
